The stock of Viking Therapeutics Inc (VKTX) has seen a -9.30% decrease in the past week, with a -7.03% drop in the past month, and a -10.29% decrease in the past quarter. The volatility ratio for the week is 5.15%, and the volatility levels for the past 30 days are at 3.59% for VKTX.. The simple moving average for the past 20 days is -3.58% for VKTX’s stock, with a -36.53% simple moving average for the past 200 days.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
The stock has a 36-month beta value of 0.64. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VKTX is 108.99M, and at present, short sellers hold a 24.51% of that float. On June 18, 2025, the average trading volume of VKTX was 3.71M shares.
VKTX) stock’s latest price update
The stock of Viking Therapeutics Inc (NASDAQ: VKTX) has decreased by -1.97 when compared to last closing price of 26.96.Despite this, the company has seen a loss of -9.30% in its stock price over the last five trading days. zacks.com reported 2025-06-16 that Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock’s price, do they really matter?
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Cantor Fitzgerald repeating the rating for VKTX by listing it as a “Overweight.” The predicted price for VKTX in the upcoming period, according to Cantor Fitzgerald is $104 based on the research report published on April 29, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $30. The rating they have provided for VKTX stocks is “Neutral” according to the report published on April 08th, 2025.
Scotiabank gave a rating of “Sector Outperform” to VKTX, setting the target price at $102 in the report published on February 13th of the current year.
VKTX Trading at -0.14% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.66% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from Rouan Sarah Kathryn, who purchase 1,240 shares at the price of $24.15 back on Mar 31 ’25. After this action, Rouan Sarah Kathryn now owns 1,240 shares of Viking Therapeutics Inc, valued at $29,943 using the latest closing price.
Lian Brian, the President & CEO of Viking Therapeutics Inc, sale 194,490 shares at $42.75 during a trade that took place back on Jan 06 ’25, which means that Lian Brian is holding 2,366,570 shares at $8,313,601 based on the most recent closing price.
Stock Fundamentals for VKTX
The total capital return value is set at -0.2. Equity return is now at value -14.40, with -13.98 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -133.99. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -2610.86.
Currently, EBITDA for the company is -109.52 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 44.25.
Conclusion
To sum up, Viking Therapeutics Inc (VKTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
